Recent advances in molecular genetics have revealed the mechanisms underlying a variety of inherited human disorders. Among them, mutations in G protein-coupled receptors have clearly demonstrated two types of abnormalities, namely loss of function and constitutive activation of the receptors. Thromboxane A2 (TXA2) receptor is a member of the family of G protein-coupled receptors and performs an essential role in hemostasis by interacting with TXA2 to induce platelet aggregation. Here we identify a single amino acid substitution (Arg60-->Leu) in the first cytoplasmic loop of the TXA2 receptor in a dominantly inherited bleeding disorder characterized by defective platelet response to TXA2. This mutation was found exclusively in affected members of two unrelated families with the disorder. The mutant receptor expressed in Chinese hamster ovary cells showed decreased agonistinduced second messenger formation despite its normal ligand binding affinities. These results suggest that the Arg60 to Leu mutation is responsible for the disorder. Moreover, dominant inheritance of the disorder suggests the possibility that the mutation produces a dominant negative TXA2 receptor. namely loss of function and constitutive activation of the receptors. Thromboxane A2(TXA2) receptor is a member of the family of G protein-coupled receptors and performs an essential role in hemostasis by interacting with TXA2 to induce platelet aggregation. Here we identify a single amino acid substitution (Arg4-Leu) in the first cytoplasmic loop of the TXA2 receptor in a dominantly inherited bleeding disorder characterized by defective platelet response to TXA2. This mutation was found exclusively in affected members of two unrelated families with the disorder. The mutant receptor expressed in Chinese hamster ovary cells showed decreased agonist-induced second messenger formation despite its normal ligand binding affinities. These results suggest that the Arg'0 to Leu mutation is responsible for the disorder. Moreover, dominant inheritance of the disorder suggests the possibility that the mutation produces a dominant negative TXA2 receptor. (J. Clin. Invest.
Introduction
A large number of G protein-coupled receptors have been identified and shown to induce their intracellular responses via cou-S-145, 5Z-7-(3-endo-phenylsulphonylamino bicyclo [2.2.1] hept-2-exo-yl) heptenoic acid; STA2, 9,1 1-epithio-1 1,12-methano-TXA2.
pling to different classes of guanine nucleotide-binding proteins (G proteins) .' Given that numerous physiologically important functions are mediated by G protein-coupled receptors, it is expected that abnormalities in G protein-coupled receptors can underlie a variety of human diseases. Indeed, several mutations in G protein-coupled receptors have been shown to be associated with human genetic diseases, which result from either loss of function or constitutive activation of the affected receptors (see references 1-3 for reviews).
Loss of function of a G protein-coupled receptor has been typically shown in congenital nephrogenic diabetes insipidus, an X-linked recessive disorder in which mutations in the V2 vasopressin receptor are responsible for the resistance to the antidiuretic action of the hormone in the kidney (4, 5) . Because the gene for the receptor is on the X chromosome, any loss of function mutation results in the clinically apparent disease in males. On the other hand, some mutations have been shown to cause constitutive activation of the luteinizing hormone receptor in familial male precocious puberty (6) and rhodopsin in a severe form of retinitis pigmentosa (7) . These constitutively active mutations are sure to produce a dominant phenotype; i.e., the diseased state is inherited in a dominant manner. Loss of function mutations can also lead to a dominant phenotype, if half of the gene product is not sufficient for normal function. The other mechanism that has not been identified clearly yet but can potentially cause a genetic disease is a dominant negative mutation, which, if genetically encoded, should manifest itself as a defective function of the receptor with a dominant inheritance.
We have previously cloned the human TXA2 receptor and shown that it belongs to the superfamily of G protein-coupled receptors (8) . It mediates the aggregation of platelets to TXA2, a major arachidonic acid metabolite, by activating the phospholipase C (PLC) cascade via a G protein-coupled pathway (9) (10) (11) . The physiological importance of the TXA2-mediated signaling pathway has been demonstrated in a group of patients whose hemostatic defects were found to be associated with platelet unresponsiveness to TXA2 (12) (13) (14) (15) (16) (17) (18) (19) . Recently, we have reported two unrelated patients with a mild bleeding disorder whose platelets showed impaired aggregation responses to TXA2 and its analogues, despite the normal response to thrombin (20, 21) . Although the patients' platelets exhibited normal binding activities to TXA2 analogues, they showed decreased GTPase activity and second messenger formation when stimulated by 9,1 1-epithio-I1,12-methano-TXA2 (STA2), a stable TXA2 agonist (20) (21) (22) . These findings led us to speculate that the defect in the patients is due to impaired coupling of the TXA2 receptor to the G protein, which is caused by an abnormality of the TXA2 receptor itself.
Here we demonstrate a mutation in the first cytoplasmic loop of the TXA2 receptor exclusively in affected members of two unrelated families with the disorder. Consistently, the mutant receptor expressed in Chinese hamster ovary (CHO) cells shows unaltered ligand binding affinities but decreased STA2-induced activation of PLC, when compared to the wild-type receptor. Moreover, we show that this defect of the platelets is inherited dominantly.
Methods
Subjects. Two unrelated patients T.T. (20, 22) (20) .
Platelet aggregation study. Platelet-rich plasma (PRP) and plateletpoor plasma (PPP) were prepared from the family members and control subjects, as described previously (20) . Platelet concentration of PRP was adjusted to 3 x 108 platelets/ml by autologous PPP. Washed platelet suspensions were prepared as previously described (20) . The concentration of the washed platelets was also adjusted to 3 X 10' platelets/ml.
The aggregation studies were performed in PRP for STA2-, ADP-, and epinephrine-induced aggregation, and in washed platelets for thrombininduced aggregation. The aggregation was monitored essentially by the method of Born (23). The PRP or washed platelet suspension was placed in a tube, and the increase in light transmission was followed at 370C in a dual-channel aggregometer (NKK Hematracer 1 model PAT-2A; Niko BioScience Co., Tokyo, Japan). The light transmission of PRP or washed platelet suspension was set at 0% and that of PPP or buffer at 100%.
Amplification of platelet mRNA. Total RNA was extracted from platelets of healthy volunteers and the patients (T.T. and Y.O.) by the acid guanidium-phenol-chloroform (AGPC) method (24) . -10 jug of total RNA was recovered from the platelets of 50 ml blood sample. 1 ,ug of total RNA was reverse-transcribed in a volume of 20 1l (25) and amplified by PCR using primers next to the coding region of the human TXA2 receptor (forward primer, 5 '-GTCTGCAGCATCGGCCTGATG-3'; reverse primer, 5'-GAGGGGCGCTCTGTCCACTT-3') (8) . PCR was performed in a final volume of 20 jA, containing 2 pIl reverse transcription (RT) reaction mixture, 50 mM KCl, 10 mM Tris-HCI (pH 8.8), 1.5 mM MgCl2, 0.1% Triton X-100, 10% dimethylsulfoxide, 0.25 mM dNTPs, 1 U Taq Polymerase (Wako Pure Chemical Industries Ltd., Osaka, Japan), and 20 pmol of each primer. After denaturation at 94°C for 2 min, 35 cycles (94°C for 1 min, 64°C for 1 min, 72°C for 1.5 min) were followed by a final elongation step for 3.5 min at 72°C. PCR products were electrophoresed, excised, purified using Geneclean II (BIO 101, Inc., Vista, CA), and blunt-end-ligated to pBluescript H SK+ (Stratagene, LaJolla, CA). Plasmid subclones were sequenced by the dideoxy method.
Genomic studies. Genomic DNA was prepared from white blood cells of the patients (T.T. and Y.O.), family members of the patient T.T., and control subjects as described (26) . A 320-bp fragment was amplified by PCR, using primers 5 '-ATGTGGCCCAACGGCAGTTC-3' and 5 '-AAGCGACAGAGACGGCAGCC-3'. PCR was done as described in RT-PCR except that 0.1 Aug genomic DNA was used instead of RT reaction mixture as a template and that the annealing temperature was lowered to 62°C. PCR products were purified from a 2% agarose gel, digested with HhaI (TOYOBO Co. Ltd., Osaka, Japan), separated on a 10% polyacrylamide gel, and visualized with ethidium bromide.
Expression of wild-type and mutant TXA2 receptors. cDNAs encoding the wild-type and mutant TXA2 receptors were inserted into a mammalian expression vector, pEF-BOS (27) with a blasticidin S-resistance marker (Funakoshi Co. Ltd., Tokyo, Japan) and introduced into the CHO cells by the calcium phosphate method (28) . Stable transformants were cloned by selection in the a-modified minimal essential medium containing 10% FCS and 15 ng/ml blasticidin S (Funakoshi Co. Ltd.). For ligand binding assay, cells were cultured in 15 cm dishes to confluency and harvested as described previously (29) . Cells were washed once and suspended at 1 x 107 cells/ml in a buffer containing 20 mM Hepes (pH 7.4), 140 mM NaCl, 5 mM KCl, and 5 mM MgCl2. Binding assays were performed as described (30) . For phosphatidylinositol (PI) turnover, cells were cultured in six-well plates to 90% confluency in the medium described above and then incubated for 20 h in inositolfree DME with 10% dialyzed FCS containing 1 MCi/ml myo-[2-3H]-inositol. The cells were washed with Hepes-buffered saline and preincubated with 10 mM LiCl in Hepes-buffered saline at 370C for 10 min. Then various concentrations of STA2 were added to each medium. After 5 min incubation, the medium was removed and the reaction was terminated by 1 ml of 5% TCA. The generation of inositol 1,4,5-triphosphate (UP3) was measured as described (31) .
Results
Identification of a family with defective platelet response to TXA2. We previously described a patient (T.T.) with a mild bleeding disorder characterized by defective platelet response to TXA2 (20, 22) . The patient's platelets showed defective aggregation response to STA2 (Fig. 1 A) , although they responded normally to thrombin (Fig. 1 B) . To determine whether this platelet disorder is hereditary, platelet functions of five additional family members were studied. The patient's daughter showed a similar but slightly milder defect in platelet aggregation response to STA2 (Fig. 1 C) . The son and the brother of the patient showed similar impairments of aggregation to that of his daughter (data not shown). On the other hand, his sister showed normal response ( Fig. 1 C) , and so did his wife (data not shown). The aggregation responses to 2 sM ADP and 5 MM epinephrine in the patient's daughter (Fig. 1, D and E), as well as his brother and son (data not shown), were suppressed. Again, these results indicate a defect in platelet responsiveness to TXA2, since TXA2 serves to amplify the platelet response to weak agonists such as ADP and epinephrine. There was no history of consanguinity. Thus, this platelet disorder appears to be transmitted as an autosomal dominant trait, probably due to a defect in the TXA2 receptor gene. We therefore decided to search for a mutation in the TXA2 receptor.
Identification of a mutation in the TXA2 receptor. To search for a mutation in the TXA2 receptor that might cause the bleeding disorder in this family, the entire coding region of the TXA2 receptor cDNA (8) was amplified by the RT-PCR method from the patient (T.T.) platelet RNA, and the PCR products were subcloned and sequenced. All the clones sequenced (more than 10 clones) contained a single base change (G-8T) at nucleotide 179 (Fig. 2 A) , resulting in the substitution of a leucine (CTC) for the arginine (CGC) at the 60th amino acid which is located in the first cytoplasmic loop of the TXA2 receptor (Fig. 2 B) .
Arg' corresponds to a highly conserved basic residue among G protein-coupled receptors (Fig. 2 C) . This mutation was not detected in cDNA fragments generated from normal individuals, thus excluding the possibility of a polymorphism. These results indicate that either the patient is homozygous for this mutation or only the mutated allele is expressed. Genomic analyses offamily members. Because the mutation destroys a HhaI restriction enzyme digestion site (GCGC), the mutation can be detected more easily by analyzing the HhaI digestion pattern of PCR products. As shown in Fig. 3 A, the G-'T transition identified here destroys the third HhaI site of PCR products, producing the 117 bp fragment which is larger than the wild-type 94 bp fragment when PCR products are digested with HhaI. Genomic analysis by this method demonstrated that the patient (T.T.) was indeed homozygous and his brother and two children were heterozygous for the mutation (Fig. 3 B) . Consistently, his wife and sister had no mutation in either allele. In each case, the accordance of the expression of either the normal or the mutated allele to the genotype was confirmed by RT-PCR followed by HhaI digestion (data not shown). No amino acid mutation was encoded in the normal allele of heterozygotes. These analyses of the family members showed a complete correspondence of the mutant allele with the impairment in platelet aggregation. Furthermore, another patient (Y.O.) from an unrelated family with a similar defect in platelet functions (21) (Fig. 4 A) . The specific [3H]S-145 binding to wildtype and mutant receptors was displaced similarly by STA2 (Ki = 12.0 and 13.3 nM for the wild-type and mutant receptors, respectively). These findings are consistent with the observation that the patients' platelets have normal binding activities to TXA2 analogues (20) (21) (22) . Then, both cell lines were examined for the activation of the PLC cascade. In the cells expressing the wild-type TXA2 receptor, STA2 produced a concentrationdependent increase in 1P3 production with a maximal stimulation of 6.3-fold (Fig. 4 B) . In contrast, the mutant TXA2 receptor produced only a twofold increase in [P3 production (Fig. 4  B) . The responses to thrombin (acting through endogenous receptors) were similar in both cell lines (40% and 42% increase in [P3 production for the wild-type and mutant receptors, respectively). These results indicate that the mutant receptor is impaired in its ability to produce agonist-induced PI hydrolysis. Thus, the expression of the mutant receptor resulted in the functional abnormality equivalent to that associated with the patients.
Discussion
We have shown that a mutation in the TXA2 receptor is associated with a bleeding disorder characterized by defective platelet response to TXA2. This mutation was identified in two unrelated patients with the disorder, who showed a similar defect in platelet responsiveness to TXA2 (Fig. 1, A and B; references 20-22) . Their platelets exhibit impaired second messenger formation induced by a TXA2 agonist despite normal ligand binding activities (20) (21) (22) (34) , human a2c-adrenergic receptor (35) , human ,31-adrenergic receptor (36) , human substance P receptor (37) , and human TSH receptor (38) are included. Conserved basic residues are boxed.
logues compared to the wild-type receptor, but was impaired in its ability to mediate agonist-induced stimulation of PLC (Fig.  4) . Investigations of family members of one patient (T.T.) suggested that this disorder is inherited as an autosomal dominant trait (Fig. 1, C-E) . Consistent with its autosomal inheritance, the TXA2 receptor gene has been mapped on a tip of the short arm of human chromosome 19 (32). Furthermore, genomic analyses revealed that the heterozygotes for the mutation demonstrate a similar, but slightly weak, phenotype of the impaired platelet aggregation to a TXA2 agonist compared to the homozygote ( Fig. 1 and Fig. 3 B) . This may not be explained with haploid insufficiency, since it has been shown that less than half the number of receptors are sufficient for irreversible aggregation of platelets by a TXA2 agonist (33) . These results indi- (39) . In addition, a two-amino acid deletion and a double replacement in the first cytoplasmic loop of the bovine rhodopsin showed a loss and a reduction of light-dependent transducin activation, respectively (40) . It is of further interest that while the present mutation did suppress aggregation response to STA2, the agonist evoked platelet shape change (Fig. 1 A) and phospholipase A2 activation (22) in the patients' platelets, indicating that the mutation found in this study may not abolish all of the signal transduction pathways through the TXA2 receptor. It is possible that this mutation specifically impairs the coupling of the receptor to the G protein linked to PLC.
Mutations in G protein-coupled receptors have been shown to cause human diseases (1-3), by either loss of function (4, 5) or constitutive activation (6, 7) of the mutated receptors. In addition to these well-defined mechanisms, the present study suggests the possibility of a dominant negative G protein-coupled receptor that can cause a human disease with a dominant inheritance. The mutant receptor could function either by interacting nonfunctionally with the G protein or by interacting with the wild-type receptor to create inactive multimeric receptors. The latter possibility is consistent with the idea that G proteincoupled receptors can interact at a molecular level, as has been demonstrated in the studies with muscarinic receptors (41) . The existence of muscarinic dimers has been postulated based on an analysis of the agonist-induced binding properties of muscarinic receptors (42, 43). Although further biochemical analyses will be required to elucidate the detailed mechanism of the dominant negative receptor function, the present study indicates a novel category of human disease that is caused by a dominant negative mutation of a G protein-coupled receptor.
Based on its sequence homology to other G protein-coupled receptors, the TXA2 receptor is thought to have the topography represented in Fig. 2 B. The Arg ' is located in the first cytoplasmic loop (Fig. 2 B) and corresponds to a highly conserved basic residue among most of the G protein-coupled receptors (Fig. 2 C, references 34-38) . The cytoplasmic domains are implicated a priori in the receptor-G protein interaction. Although the third loop and the COOH-terminal domain have been strengthened more than the first cytoplasmic loop, the conservation of the basic residue in the first cytoplasmic domain
